Greig Rooney joins CPI as Managing Director for Pharma and HealthTech

An accomplished life sciences leader with more than 20 years of experience across pharmaceuticals, vaccines, and biopharmaceutical manufacturing, Greig has a proven track record of transforming organisations and developing high-performing teams. His career has spanned the UK, Europe, and the USA, most recently as Managing Director at Valneva Scotland, where he led major national and international initiatives and worked closely with highly skilled teams to deliver strategic programmes of national importance. 

Greig’s leadership in driving excellence in safety, quality, and regulatory compliance, alongside his strategic mindset and collaborative style, has made a real impact across the industry. His approach exemplifies the kind of agility and innovation that CPI exists to enable. 

Central to Greig’s leadership is his belief that every person contributes to a company’s mission. He is passionate about empowering people, hearing diverse voices, and creating environments where innovation can thrive. 

At CPI, Greig will drive the strategic direction of our Pharma and HealthTech portfolio, fostering collaboration across academia, industry, government, and the investment community to accelerate the scale-up of innovative products and processes. He aims to connect the dots between sectors – from pharmaceuticals and medical devices to emerging digital and AI-enabled technologies – to unlock new opportunities for economic growth and patient impact. 

Diagnosed with type 1 diabetes at 17 after surviving malaria as a child, Greig has a deeply personal understanding of how innovation can change lives. Now using an artificial pancreas system to manage his own condition, he is passionate about marrying medical technology with targeted therapies to improve the quality of life for people living with chronic diseases. 

Greig Rooney said:

“CPI’s mission to turn great ideas into products and processes that change lives really resonates with me. Translational innovation is the bridge between science and impact – it delivers economic growth, strengthens national resilience, and ultimately improves lives for patients and communities across the UK. 

“I’m genuinely looking forward to working with the exceptionally talented employees across the CPI network in Scotland and the wider UK, as well as our many valued stakeholders and customers. By bringing together people and ideas from different disciplines, backgrounds, and industries, we can make remarkable things happen. I’m excited to help CPI build on its strong foundations, empower its teams, and create even greater impact for patients and society.” 

Frank Millar, CEO at CPI, said:

“We’re delighted to welcome Greig Rooney to CPI. His experience leading large-scale organisations, coupled with his passion for people, collaboration, and innovation, makes him a perfect fit for our mission. 

“At Valneva, Greig led transformational initiatives – from delivering the world-class Almeida facility to driving excellence in safety, quality, and regulatory compliance. His strategic mindset and collaborative approach have made a real impact across industry and government alike. 

“Greig’s appointment strengthens CPI’s capability in Pharma and HealthTech at a time when digitalisation, advanced manufacturing, and data-driven discovery are transforming the industry and creating new opportunities to scale UK innovation. His vision for a more connected innovation ecosystem aligns perfectly with our ambitions across the High Value Manufacturing Catapult.” 

Greig also brings significant experience in stakeholder engagement and sector leadership. As Chair of the Scottish Patient Awareness Council, he has worked closely with government, universities, and the third sector to build stronger, more connected communities of innovation across Scotland. 

He will champion deeper and more strategic ed collaboration across industry and the Catapults that serve the life sciences sector, helping to align efforts, share expertise, and drive tangible outcomes that strengthen the UK’s position as a global leader in scaling new technology for improved patient outcomes, productivity and economic growth.